Development of a new class of antibiotics brings life to the clinical problem of drug-resistant bacteria

Development of a new class of antibiotics brings life to the clinical problem of drug-resistant bacteria

    In recent years, the rapid change of drug-resistant bacteria has made clinicians encounter great challenges in the treatment of patients with infectious diseases. Gram-negative bacterial infections are common in nosocomial infections, and most of them are systemic infections. The prognosis of patients is quite poor, and the worst is death. Among the Gram-negative bacteria, the most serious problem is the problem of carbapenem resistance, which has been listed by the World Health Organization (WHO) as an issue that urgently needs the input of new antibiotics. Therefore, teacher Tseng Sung-Pin from the Department of Medical Laboratory Biotechnology and Dr. Lu Po-Liang, Dean of the Faculty of Medicine, and Dr. Yang Tsung-Ying, a student, formed a team to study the development of new antibiotics—a new class of antibiotics, organo-tellurides. The development process is guided by multiple resources (such as the campus's industry-university office, SPARK program, biomedical commercialization center, etc.), and gradually corrects the development direction and strategy, from the original policy of only targeting a single drug resistance problem to the treatment of the overall Gram The category of negative bacteria is expected to increase the value of drug patents. In addition, because drug development cannot be fully completed by a single team, laboratory or even a company, it is necessary to use a team or company with rich experience in each stage through a relay-style research and development process. Conduct research and development to reduce risks (such as pre-clinical, first and second phases, third phases, etc.), so the team also actively participates in industry-university matchmaking, such as teacher Tseng Sung-Pin and Dr. Lu Po-Liang guiding students to participate in domestic innovation and entrepreneurship programs, through the SPARK program Participate in biomedical talent training held abroad and the 19th National Innovation Award in 2022, etc., hoping to expose the team's drug technology through these opportunities, seek opportunities for technology licensing or even transfer, so that organo-telluride can be used as a new class of antibiotic entered the clinic to treat patients with Gram-negative infections.

    According to statistics and experience, compared with cancer drugs and chronic drugs, the development of antibiotics has much less revenue than that of cancer drugs and chronic drugs. As a result, most pharmaceutical companies are reluctant to touch the research and development of this field. Therefore, the research and development investment of the academic and research circles has become an important part of the development of antibiotics. , hoping to take advantage of this opportunity of winning the National Innovation Award for Academic Research and Innovation, to increase the exposure opportunities of our team’s technology, and to serve as an introduction to attracting jade, so that more academic and research teams are more willing to invest in the development of antibiotics to alleviate the epidemic. The status quo of the gradual collapse of the clinical antibiotic wall.

Application and Highlights:

1.The team is committed to developing new class of antibiotic for bacterial infections

2.Won the 19^th National Innovation Award Academic Research Innovation Award

Research Team Members:

Tseng Sung-Pin  https://wp.kmu.edu.tw/tsengsp/

Lu Po-Liang  https://cmed.kmu.edu.tw/index.php/zh-tw/%E5%AD%B8%E9%99%A2%E7%B0%A1%E4%BB%8B/%E9%99%A2%E9%95%B7%E7%B0%A1%E4%BB%8B

Yang Tsung-Ying https://www.isu.edu.tw/newsite/deptfa.php?dept_mno=875&dept_id=10&aid=1B125

Representative Department: Drug Development and Value Creation Research Center, Kaohsiung Medical University

Introduction of Research Team:

The laboratory team of Dr. Tseng Sung-Pin, Department of Medical Technology, is also one of the pharmaceutical counseling teams of SPARK TAIWAN (Taiwan Biomedical and Medical Materials Translation Value-Added Talent Training Program) of Kaohsiung Medical University. The infection of drug-resistant bacteria has become a common problem in global medical clinics. The most serious problem among drug-resistant bacteria is "Carbapenem resistance". However, it is difficult to develop a new class of antibiotics, so that pharmaceutical companies can only improve them with similar structures or with inhibitors, and the problem of drug resistance that is likely to be caused by new skin and old bone antibiotics recurs, making drugs Loses effect quickly. The team has currently developed a new small molecule compound antibiotic, which has a better therapeutic effect than the current clinical drug. It has passed the US patent provisional case. In the future, it will further complete the preclinical test and apply for the qualification of an experimental new drug, and then hope to transfer the technology to a pharmaceutical company. In this way, it can create vitality for the problem of clinical drug-resistant bacteria.

Contact Email:

Tseng Sung-Pin (tsengsp@kmu.edu.tw)；

Yang Tsung-Ying (zegma040899@gmail.com)

Publication:

Pharmaceuticals (Basel). 2021 Aug 12;14(8):795.

Pharmaceuticals (Basel). 2021 Aug 21;14(8):823.

Microbiol Spectr. 2023 Mar 6;e0149622.

Full-Text Article:

https://www.mdpi.com/1424-8247/14/8/795

https://www.mdpi.com/1424-8247/14/8/823

https://journals.asm.org/doi/10.1128/spectrum.01496-22